About this trial
This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
English speaking
Age 18-75
ASA physical status 1-3
Undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels)
Disqualifiers
Age <18 or >75
ASA IV or V
Non-English speaking
BMI >40
Trial design
Parallel
Treatments tested in this trial
ESP Block with Bupivacaine
DrugCervical and lumbar ESP blocks performed under ultrasound guidance using plain bupivacaine.
ESP Block with Bupivacaine + Liposomal Bupivacaine
DrugCervical and lumbar ESP blocks performed under ultrasound guidance using bupivacaine admixed with liposomal bupivacaine.
Treatment groups
Trial outcomes
Primary outcomes
Postoperative Pain as measured by opiate consumption
Morphine MilliEquivalents
Secondary outcomes
Postoperative Pain at rest and with movement as measured by patient reported pain scores
Numeric Rating Scale (0-10) 0 being no pain, 10 being worst pain imaginable
Discharge Readiness
Hospital and PACU Length of Stay
Postoperative Pain Severity as measured by required time for patient controlled-analgesia
Duration of patient controlled analgesia use
Incidents of post-operative nausea and vomiting
Post-operative Nausea and Vomiting
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: